67 related articles for article (PubMed ID: 38623087)
1. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
2. A case report of pegcetacoplan use for a pregnant woman with paroxysmal nocturnal hemoglobinuria.
Du W; Mei L
Res Pract Thromb Haemost; 2024 May; 8(4):102435. PubMed ID: 38846741
[TBL] [Abstract][Full Text] [Related]
3. Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria.
Peffault de Latour R; Griffin M; Kelly RJ; Szer J; de Castro C; Horneff R; Tan L; Yeh M; Panse J
Blood Adv; 2024 Jun; 8(11):2718-2725. PubMed ID: 38593241
[TBL] [Abstract][Full Text] [Related]
4. Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.
Xu B; Kang B; Chen J; Li S; Zhou J
Blood Rev; 2024 Jul; 66():101210. PubMed ID: 38811284
[TBL] [Abstract][Full Text] [Related]
5. Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings.
Kelly RJ; Nishimori H; Horneff R; Hillmen P; Al-Adhami M; Lallier S; Gerber GF
Res Pract Thromb Haemost; 2024 May; 8(4):102416. PubMed ID: 38812989
[TBL] [Abstract][Full Text] [Related]
6. Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors.
Obara N; Usuki K; Hayashi T; Fujii M; Ikezoe T
Int J Hematol; 2024 Mar; 119(3):255-264. PubMed ID: 38243016
[TBL] [Abstract][Full Text] [Related]
7. Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria.
Füreder W; Valent P
Ann Hematol; 2024 Jun; ():. PubMed ID: 38918202
[No Abstract] [Full Text] [Related]
8. Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
Di Matteo S; Freilone R; Bruno GM; Notaro R; Moumene S; Martone N; Teruzzi C; Ciccarone A; Colombo GL
Clinicoecon Outcomes Res; 2024; 16():225-232. PubMed ID: 38623087
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
Wong RSM
Ther Adv Hematol; 2022; 13():20406207221114673. PubMed ID: 35923770
[TBL] [Abstract][Full Text] [Related]
11. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
Heo YA
Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA.
Fishman J; Wilson K; Drzewiecka A; Pochopień M; Dingli D
J Comp Eff Res; 2023 Oct; 12(10):e230055. PubMed ID: 37655691
[No Abstract] [Full Text] [Related]
13. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
